The TB structural genomics consortium: Providing a structural foundation for drug discovery

Celia W. Goulding, Marcin Apostol, Daniel H. Anderson, Harindarpal S. Gill, Clare V. Smith, Mack R. Kuo, Jin KukYang, Geoffrey S. Waldo, Se Won Suh, Radha Chauhan, Avinash Kale, Nandita Bachhawat, Shekhar C. Mande, Jodie M. Johnston, J. Shaun Lott, Edward N. Baker, Vickery L. Arcus, David Leys, Kirsty J. McLean, Andrew W. MunroJoel Berendzen, Vivek Sharma, Min S. Park, David Eisenberg, James Sacchettini, Tom Alber, Bernhard Rupp, William Jacobs, Thomas C. Terwilliger

Research output: Contribution to journalReview articlepeer-review

77 Scopus citations


Structural genomics, the large-scale determination of protein structures, promises to provide a broad structural foundation for drug discovery. The tuberculosis (TB) Structural Genomics Consortium is devoted to encouraging, coordinating, and facilitating the determination of structures of proteins from Mycobacterium tuberculosis and hopes to determine 400 TB protein structures over 5 years. The Consortium has determined structures of 28 proteins from TB to date. These protein structures are already providing a basis for drug discovery efforts.

Original languageEnglish (US)
Pages (from-to)121-141
Number of pages21
JournalCurrent Drug Targets - Infectious Disorders
Issue number2
StatePublished - 2002
Externally publishedYes

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Microbiology (medical)


Dive into the research topics of 'The TB structural genomics consortium: Providing a structural foundation for drug discovery'. Together they form a unique fingerprint.

Cite this